Sentonix, Inc.
Arlington, MA
Funding event
The round itself, as filedInferred stageSeries A
Sold of offered$12.7M of $21.2M
Filed2026-08-20
Days since filing44
- Exemption claimed
- Rule 506(b)
- First-ever Form D
- No
- Date of first sale
- 2026-08-13
Investors
No investors named: Form D does not list them
Officers on the filing
Names and roles as filed; addresses are never stored- Karl SchmidtExecutive Officer
- John BeaverExecutive Officer · Director
- Kenan TurnaciogluExecutive Officer · Director
- Jack HoppinDirector
Health flags
Three flags, each with the raw inputs behind it · as of 2026-10-03UndersubscribedNot flagged59.9% sold1.7 months since first sale
Prior raiseNot flaggedPrior raise not known—
AmendedNot flaggedNo amendmentNo D/A on file
Open roles
On the employer's own careers page · check date not recorded0
Pre-posting windowNot enough dataShown once this sector and stage have 20 observed lags from filing to first posting.
No open roles foundWe read careers pages daily.
Also raised in Health & bio
Same sector, 28 days to 2026-10-04Altay TherapeuticsSeries A · $15.7M of $45.1M · San Carlos, CAQuietCarebilitySeries A · $8.8M of $8.8M · Richardson, TXQuiet
75 rounds in Health & bio in the 28 days to 2026-10-02, against 71 in the 28 days before.